KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Gains from Sales and Divestitures (2019 - 2022)

Pacific Biosciences Of California (PACB) has 4 years of Gains from Sales and Divestitures data on record, last reported at $2.6 million in Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures rose 43.6% year-over-year to $2.6 million; the TTM value through Dec 2022 reached $2.6 million, up 43.6%, while the annual FY2022 figure was $2.6 million, 43.6% up from the prior year.
  • Gains from Sales and Divestitures reached $2.6 million in Q4 2022 per PACB's latest filing, up from $2.4 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.6 million in Q4 2022 and bottomed at $2026.0 in Q2 2022.
  • Average Gains from Sales and Divestitures over 4 years is $1.1 million, with a median of $938000.0 recorded in 2020.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 995.0% in 2020, then crashed 99.86% in 2022.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $204000.0 in 2019, then skyrocketed by 390.2% to $1.0 million in 2020, then skyrocketed by 79.8% to $1.8 million in 2021, then soared by 43.6% to $2.6 million in 2022.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $2.6 million in Q4 2022, $2.4 million in Q3 2022, and $2026.0 in Q2 2022.